Hodgkin Lymphoma News and Research

RSS

People who drink alcohol have a lower risk of non-Hodgkin's lymphoma

People who drink alcohol have a lower risk of non-Hodgkin's lymphoma (NHL) than non-drinkers, researchers at Yale's Department of Epidemiology and Public Health (EPH) write in an article published in Lancet Oncology.

15 Aug 2005

People who drink alcohol have a lower risk of non-Hodgkin's lymphoma

People who drink alcohol have a lower risk of non-Hodgkin’s lymphoma (NHL) than non-drinkers, researchers at Yale’s Department of Epidemiology and Public Health (EPH) wrote recently in an article published in Lancet Oncology.

19 Jul 2005

Patients suffering from oral cancer have increased levels of certain bacteria in their saliva

Six common species of bacteria were found at significantly higher levels in the saliva of patients with oral squamous cell carcinoma (OSCC) than in the saliva of healthy individuals.

6 Jul 2005

New discoveries in treatment for patients with non-Hodgkin's lymphoma

Three scientific studies - each highlighting new discoveries in treatment for patients with non-Hodgkin's lymphoma - were announced at the Society of Nuclear Medicine's 52nd Annual Meeting June 18–22 in Toronto.

20 Jun 2005

Immunomedics awarded U.S. and Australian patents

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

16 Jun 2005

MabThera highly effective in treating rheumatoid arthritis

Results from the DANCER study presented today revealed that MabThera significantly improves symptoms in heavily treated patients who are affected by moderate-to-severe rheumatoid arthritis (RA), a painful and debilitating disease of the joints.

9 Jun 2005

Drinking alcohol may lower risk of developing non-Hodgkin's lymphoma

People who drink alcohol may have a lower risk of developing non-Hodgkin's lymphoma (NHL) - a type of cancer that affects the lymphatic system, suggests a study published online by The Lancet Oncology.

6 Jun 2005

Long-term outcomes studied for stem cell transplant recipients

Improved techniques and supportive care have resulted in a growing number of long-term survivors of stem cell transplants, though little is known about the impact transplants have on patients’ lives long after treatment.

23 May 2005

Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active anti-retroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

18 May 2005

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Researchers at the Keck School of Medicine of the University of Southern California and colleagues have found a way to streamline a new form of treatment for patients with non-Hodgkin's lymphoma.

18 May 2005

Zevalin safe and effective for non-Hogdkin's lymphoma patients

According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate Zevalin (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor.

17 May 2005

Tumor vasculature has become an attractive target in the treatment of cancer.

Treatment with a protein fused to an antibody in tumor-bearing mice led to coagulation of the blood within the tumor blood vessels, tumor tissue death, and tumor growth delay, according to a new study in the May 18 issue of the Journal of the National Cancer Institute.

17 May 2005

New predictor for blood transplant success

The success of blood stem cell transplants used to treat diseases such as leukemia, Hodgkin’s lymphoma and aplastic anemia may soon become more predictable, thanks to a discovery made by researchers at the University of British Columbia.

11 May 2005

Key discovery about non-Hodgkin lymphoma

There is a surprise benefit to being either an only child, the oldest sibling or even enduring some allergies – you are significantly less likely to develop non-Hodgkin lymphoma (NHL), according to new research from the University of New South Wales (UNSW).

19 Apr 2005

Antiretroviral therapy may prevent some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

15 Mar 2005

Link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein

Researchers at the University of Pennsylvania School of Medicine have identified a link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein known to be expressed in a number of EBV-associated cancers.

15 Mar 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004